Journal Mobile Options
Table of Contents
Vol. 72, No. 5, 2005
Issue release date: December 2005
Pathobiology 2005;72:233–240

Expression of Liver-Type Fatty-Acid-Binding Protein, Fatty Acid Synthase and Vascular Endothelial Growth Factor in Human Lung Carcinoma

Kawamura T. · Kanno R. · Fujii H. · Suzuki T.
Departments of aPathology and bSurgery, Fukushima Medical University School of Medicine, Fukushima, and cDepartment of Signal Transduction, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Objective: A key enzyme of fatty acid synthesis, fatty acid synthase (FAS), is expressed in human cancers, including squamous-cell carcinoma of the lung, and long-chain fatty acids are intracellularly transported and/or taken up from blood by fatty-acid-binding proteins (FABPs). Since the liver-type (L-) FABP, a member of the FABPs, is detected in a subset of gastric adenocarcinomas, the expression of FAS, L-FABP and vascular endothelial growth factor (VEGF) was investigated in human lung carcinomas to elucidate the mechanisms of production and transportation of fatty acid(s) in cancer. Methods: Expression of L-FABP, FAS and VEGF in 199 surgically resected lung carcinomas was examined immunohistochemically. Possible associations of the expression of each protein with major clinicopathological factors were analyzed. Results: L-FABP was detected in 60% (120 of 199) of the lung carcinoma cases; detection was increased in large-cell carcinoma (80%) and adenosquamous carcinoma (83%), but low in squamous-cell carcinoma (47%) and in small-cell carcinoma (57%). Overall expression of FAS was 67.3% (134 of 199 cases) and that of VEGF was 86.8% (158 of 199 cases), respectively. Expression of L-FABP was not correlated with the FAS status, but there was a tendency to co-expression of L-FABP and VEGF. There was no association between L-FABP, FAS or VEGF expression and clinicopathological data. Conclusions: L-FABP, FAS and VEGF are highly expressed in human lung cancer, and expression of L-FABP is associated with that of VEGF but not that of FAS, suggesting that L-FABP might be involved in the uptake of fatty acid(s) from the bloodstream.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Bass NM: The cellular fatty acid binding proteins. Aspects of structure, regulation, and function. Int Rev Cytol 1988;111:143–184.
  2. Veerkamp JH, Peeters RA, Maatman RGHJ: Structural and functional features of different types of cytoplasmic fatty acid-binding proteins. Biochim Biophys Acta 1991;1081:1–24.
  3. Veerkamp J, Maatman RGHJ, Prinsen C: Fatty acid-binding proteins: structural and functional diversity. Biochem Soc Trans 1992;20:801–805.
  4. Sacchettini JC, Gordon JI: Rat intestinal fatty acid binding protein. J Biol Chem 1993;268:18399–18402.
  5. Haunerland NH, Jacobson BL, Wesenberg G, Rayment I, Holden HM: Three-dimensional structure of the muscle fatty-acid-binding protein isolated from the desert locust Schistocerca gregaria. Biochemistry 1994;33:12378–12385.
  6. Veerkamp JH, Maatman RGHJ: Cytoplasmic fatty acid-binding proteins: Their structure and genes. Prog Lipid Res 1995;34:17–52.
  7. Bennett E, Stenvers KL, Lund PK, Popko B: Cloning and characterization of a cDNA encoding a novel fatty acid binding protein from rat brain. J Neurochem 1994;63:1616–1624.
  8. Oko R, Morales CR: A novel testicular protein, with sequence similarities to a family of lipid binding proteins, is a major component of the rat sperm perinuclear theca. Dev Biol 1994;166:235–245.
  9. Chan L, Wei CF, Li WH, Yang CY, Ratner P, Pownall H, Gotto AM Jr, Smith LC: Human liver fatty acid binding protein cDNA and amino acid sequence: functional and evolutionary implications. J Biol Chem 1985;260:2629–2632.
  10. Suzuki T, Ono T: Immunohistochemical studies on the distribution and frequency of fatty-acid-binding protein positive cells in human fetal, newborn and adult liver tissues. J Pathol 1987;153:385–394.
  11. Suzuki T, Hitomi M, Ono T: Immunohistochemical distribution of hepatic fatty acid-binding protein in rat and human alimentary tract. J Histochem Cytochem 1988;36:349–357.
  12. Suzuki T, Ono T: Ontogeny of hepatic fatty acid-binding protein immunoreactivity in human liver and intestinal tract. Acta Pathol Jpn 1998;38:979–987.

    External Resources

  13. Suzuki T, Watanabe K, Ono T: Immunohistochemical demonstration of liver fatty acid-binding protein in human hepatocellular malignancies. J Pathol 1990;161:79–83.
  14. Suzuki T, Watanabe K, Hirota M, Iwafuchi M, Ono T, Aoyagi Y, Ito S: Establishment of a human hepatoblastoma model in a thymic nude mice: producibility of fatty acid-binding protein, α-fetoprotein and α-acid glycoprotein. Acta Pathol Jpn 1992;42:255–261.
  15. Hashimoto T, Kusakabe K, Watanabe K, Sugino T, Fukuda T, Nashimoto A, Honma K, Sato Y, Kimura H, Fujii H, Suzuki T: Liver-type fatty acid-binding protein is highly expressed in intestinal metaplasia and in subset of carcinomas of the stomach without association with fatty acid synthase status in the carcinoma. Pathobiology 2004;71:115–122.
  16. Sacchetti JC, Scapin G, Gopaul D, Gordon JI: Refinement of the structure of Escherichia coli-derived rat intestinal fatty acid binding protein with bound oleate to 1.75-A resolution: correlation with the structures of apoprotein and the protein with bound palmitate. J Biol Chem 1992;267:23534–23545.

    External Resources

  17. Richieri GV, Ogata RT, Kleinfield AM: Equilibrium constants for the binding of fatty acids with fatty acid-binding proteins from adipocyte, intestine, heart and liver measured with the fluorescent probe ADIFAB. J Biol Chem 1994;269:23918–23930.
  18. Burrier RE, Manson CE, Brecher P: Binding of acyl-CoA to liver fatty acid binding protein: effect on acyl-CoA synthesis. Biochim Biophys Acta 1987;919:221–230.
  19. Takikawa H, Kaplowitz N: Binding of bile acids, oleic acid, and organic anions by rat and human hepatic Z protein. Arch Biochem Biophys 1986;251:385–392.
  20. Thumser AE, Voysey JE, Wilton DC: The binding of lysophospholipids to rat liver fatty acid-binding protein and albumin. Biochem J 1994;301:801–806.
  21. Burrier RE, Brecher P: Binding of lysophosphatidylcholine to the rat liver fatty acid binding protein. Biochim Biophys Acta 1986;879:229–239.
  22. Richieri GV, Ogata RT, Kleinfeld AM: Fatty acid interactions with native and mutant fatty acid binding proteins. Mol Cell Biochem 1999;192:77–85.
  23. Richieri GV, Ogata RT, Kleinfeld AM: Thermodynamic and kinetic properties of fatty acid interactions with rat liver fatty acid-binding protein. J Biol Chem 1996;271:31068–31074.
  24. Bressler R, Wakil SJ: Studies on the mechanism of fatty acid synthesis: the conversion of malonyl coenzyme A to long chain fatty acid. J Biol Chem 1961;236:1643–1651.
  25. Wakil SJ: Fatty acid synthase, a proficient multifunctional enzyme. Biochemistry 1989;28:4523–4530.
  26. Kuhajda FP, Jenner K, Wood FD, Hennigar RA, Jacobs LB, Dick JD, Pasternack GR: Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc Natl Acad Sci USA 1994;91:6379–6383.
  27. Takahashi K, Odani S, Ono T: Isolation and characterization of three fractions (DE-I, DE-II, and DE-III) of rat liver Z-protein and the complete primary structure of DE-II. Eur J Biochem 1983;136:589–601.
  28. Piyathilake CJ, Frost AR, Manne U, Bell WC, Weiss H, Heimberger DG, Grizzle WE: The expression of fatty acid synthase (FASE) is an early event in the development and progression of squamous cell carcinoma of the lung. Hum Pathol 2000;31:1068–1073.
  29. Epstein JI, Carmichael M, Partin AW: OA-519 (fatty acid synthase) as an independent predictor of pathologic stage in adenocarcinoma of the prostate. Urology 1995;45:81–86.
  30. Gransler TS, Hardman W, Hunt DA, Schaffel S, Hennigar RA: Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival. Hum Pathol 1997;28:686–692.
  31. Jensen V, Ladekarl M, Holm-Nielsen P, Melsen F, Soerensen FB: The prognostic value of oncogenic antigen 519 (OA-519) expression and proliferative activity detected by antibody MIB 1 in node-negative breast cancer. J Pathol 1995;176:343–352.
  32. Nakamura I, Kimijima I, Zhang GJ, Onogi H, Endo I, Suzuki S, Tsuchiya A, Takenoshita S, Kusakabe T, Suzuki T: Fatty acid synthase expression in Japanese breast carcinoma patients. Int J Mol Med 1999;4:381–387.
  33. Rashid A, Pizer ES, Moga M, Hamilton SR: Elevation of fatty acid synthase expression and fatty acid synthetic activity in colorectal neoplasia. Am J Pathol 1997;150:201–208.
  34. Nemoto T, Terashima S, Kogure M, Hoshino Y, Kusakabe T, Suzuki T, Gotoh M: Overexpression of fatty acid synthase in oesophageal squamous cell dysplasia and carcinoma. Pathobiology 2001;69:297–303.
  35. Kusakabe T, Nashimoto A, Honma K, Suzuki T: Fatty acid synthase is highly expressed in carcinoma, adenoma and in regenerative epithelium and intestinal metaplasia of the stomach. Histopathology 2002;40:71–79.
  36. Hayashi T, Abe K, Suzuki H, Itoyama Y: Rapid induction of vascular endothelial growth factor gene expression after transient middle cerebral artery occlusion in rats. Stroke 1997;28:2039–2044.
  37. Torimura T, Sata M, Ueno T, Kin M, Tsuji R, Suzaku K, Hashimoto O, Sugawara H, Tanikawa K: Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma. Hum Pathol 1998;29:986–991.
  38. Yuan A, Yu CJ, Chen WJ, Lin FY, Kuo SH, Luh KT, Yang PC: Correlation of total VEGF mRNA and protein expression with histologic type, tumor angiogenesis, patient survival and timing of relapse in non-small cell lung cancer. Int J Cancer 2000;89:475–483.
  39. Storch J, Thumser AE: The fatty acid transport function of fatty acid-binding proteins. Biochim Biophys Acta 2000;1486:28–44.
  40. Murphy EJ, Prows DR, Jefferson JR, Schroeder F: Liver fatty acid-binding protein expression in transfected fibroblasts stimulates fatty acid uptake and metabolism. Biochim Biophys Acta 1996;1301:191–198.

    External Resources

  41. Wolfrum C, Buhlmann C, Rolf B, Borchers T, Spener F: Variation of liver-type fatty acid binding protein content in the human hepatoma cell line HepG2 by peroxisome proliferators and antisense RNA affects the rate of fatty acid uptake. Biochim Biophys Acta 1999;1437:28–44.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50